Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:IBIO NASDAQ:SIGA NASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$10.30+8.1%$8.28$5.65▼$10.58$332.47M1.08284,544 shs377,759 shsIBIOiBio$1.65-5.2%$1.76$0.56▼$3.82$86.44M1.26797,742 shs930,947 shsSIGASiga Technologies$4.30-0.7%$4.49$4.09▼$9.62$310.57M0.91358,454 shs278,429 shsTENXTenax Therapeutics$13.64+11.3%$12.36$5.62▼$18.38$324.93M0.98901,801 shs1.02 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies+8.08%+14.96%+3.73%+66.94%+27.63%IBIOiBio-5.17%+6.45%-10.33%-24.31%+164,999,900.00%SIGASiga Technologies-0.69%0.00%-8.12%-13.83%-30.53%TENXTenax Therapeutics+11.35%+20.39%+12.45%-2.57%+142.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$10.30+8.1%$8.28$5.65▼$10.58$332.47M1.08284,544 shs377,759 shsIBIOiBio$1.65-5.2%$1.76$0.56▼$3.82$86.44M1.26797,742 shs930,947 shsSIGASiga Technologies$4.30-0.7%$4.49$4.09▼$9.62$310.57M0.91358,454 shs278,429 shsTENXTenax Therapeutics$13.64+11.3%$12.36$5.62▼$18.38$324.93M0.98901,801 shs1.02 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies+8.08%+14.96%+3.73%+66.94%+27.63%IBIOiBio-5.17%+6.45%-10.33%-24.31%+164,999,900.00%SIGASiga Technologies-0.69%0.00%-8.12%-13.83%-30.53%TENXTenax Therapeutics+11.35%+20.39%+12.45%-2.57%+142.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 2.71Moderate Buy$15.4049.51% UpsideIBIOiBio 3.13Buy$5.00203.03% UpsideSIGASiga Technologies 2.00HoldN/AN/ATENXTenax Therapeutics 2.86Moderate Buy$38.00178.59% UpsideCurrent Analyst Ratings BreakdownLatest IBIO, TENX, FENC, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/22/2026TENXTenax Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00 ➝ $40.006/22/2026TENXTenax Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/15/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/12/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $50.006/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/8/2026IBIOiBio Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.006/5/2026IBIOiBio B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.006/1/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/22/2026FENCAdherex Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $16.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$44.64M8.05N/AN/A$1.04 per share9.90IBIOiBio$400K204.93N/AN/A$0.90 per share1.83SIGASiga Technologies$93.78M3.29$0.33 per share13.01$2.78 per share1.55TENXTenax TherapeuticsN/AN/AN/AN/A$10.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$9.74M-$0.29N/A11.20N/A-17.12%-43.87%-11.35%8/13/2026 (Estimated)IBIOiBio-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)SIGASiga Technologies$23.28M$0.2715.93N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)TENXTenax Therapeutics-$52.60M-$1.40N/AN/AN/AN/A-56.32%-53.12%8/12/2026 (Estimated)Latest IBIO, TENX, FENC, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FENCAdherex Technologies-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million5/12/2026Q3 2026IBIOiBio-$0.06-$0.07-$0.01-$0.06$0.02 millionN/A5/12/2026Q1 2026TENXTenax Therapeutics-$0.40-$0.35+$0.05-$0.35N/AN/A5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 million3/24/2026Q4 2025FENCAdherex Technologies$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million3/24/2026Q4 2025FENCAdherex Technologies$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ALatest IBIO, TENX, FENC, and SIGA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2026SIGASiga Technologiesspecial$0.604/7/20264/7/20264/23/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A6.986.78IBIOiBioN/A11.8811.88SIGASiga TechnologiesN/A3.252.38TENXTenax TherapeuticsN/A14.5214.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%IBIOiBio7.90%SIGASiga Technologies55.40%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies10.73%IBIOiBio2.75%SIGASiga Technologies2.73%TENXTenax Therapeutics3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1034.89 million31.14 millionOptionableIBIOiBio10049.68 million48.31 millionN/ASIGASiga Technologies4071.72 million69.77 millionOptionableTENXTenax Therapeutics926.52 million25.54 millionNot OptionableIBIO, TENX, FENC, and SIGA HeadlinesRecent News About These CompaniesTenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 21 at 4:13 AM | americanbankingnews.comTenax Therapeutics Announces Results of 2026 Annual MeetingJune 4, 2026 | tipranks.comTenax Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TENXMay 24, 2026 | benzinga.comTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerMay 4, 2026 | globenewswire.comTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerApril 22, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tenax Therapeutics (TENX)April 15, 2026 | theglobeandmail.comTenax Therapeutics (TENX) price target increased by 13.86% to 29.32March 27, 2026 | msn.comTenax Therapeutics: A Binary Bet With Heavy Downside LikelyMarch 18, 2026 | seekingalpha.comCantor Fitzgerald initiates coverage of Tenax Therapeutics (TENX) with overweight recommendationMarch 18, 2026 | msn.comTenax wins bullish view at Cantor ahead of pivotal readoutMarch 17, 2026 | seekingalpha.comTenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | finanznachrichten.deTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | globenewswire.comTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comTenax Therapeutics: Some Future PotentialFebruary 26, 2026 | seekingalpha.comTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026February 4, 2026 | globenewswire.comTenax Therapeutics: A Speculative BuyJanuary 9, 2026 | seekingalpha.comGuggenheim Doubles Tenax (TENX) PT, Names Stock Top PickJanuary 8, 2026 | insidermonkey.comWhy Tenax Therapeutics, Inc.’s (TENX) Stock Is Up 17.17%January 5, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, TENX, FENC, and SIGA Company DescriptionsAdherex Technologies NASDAQ:FENC$10.30 +0.77 (+8.08%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$10.30 +0.00 (+0.02%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.iBio NASDAQ:IBIO$1.65 -0.09 (-5.17%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$1.67 +0.02 (+0.97%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Siga Technologies NASDAQ:SIGA$4.30 -0.03 (-0.69%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$4.28 -0.01 (-0.35%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Tenax Therapeutics NASDAQ:TENX$13.64 +1.39 (+11.35%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$13.67 +0.03 (+0.23%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
